Mahrous Recommendation - 1 - AGA Introduces New Guideline for Crohn’s Disease 2013

270 views

Published on

Mahrous Recommendation - 1 - AGA Introduces New Guideline for Crohn’s Disease 2013

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
270
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
6
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Mahrous Recommendation - 1 - AGA Introduces New Guideline for Crohn’s Disease 2013

  1. 1. Mahrous Recommendation Based on Best Evidence , Practice Guidelines & Expert Opinion AGA Introduces New Guideline for Crohn’s Disease December 06, 2013 Waleed Mahrous Dr Waleed Kh. Mahrous http://www.gastro.org/journals-publications/news/AGA-Introduces-New-Guideline-for-Crohn-s-Disease
  2. 2. Recommendations for the induction of remission Dr Waleed Kh. Mahrous  We suggest against using thiopurine monotherapy to induce remission in patients with moderately severe Crohn’s disease (weak recommendation, moderate-quality evidence).  We suggest against using methotrexate to induce remission in patients with moderately severe Crohn’s disease (weak recommendation, low-quality evidence). Dr Waleed Kh. Mahrous http://www.gastro.org/journals-publications/news/AGA-Introduces-New-Guideline-for-Crohn-s-Disease
  3. 3. Recommendations for the induction of remission  We recommend using anti-TNF-α drugs to induce remission in patients with moderately severe Crohn’s disease (strong recommendation, moderate-quality evidence).  We recommend using anti-TNF-α monotherapy over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn’s disease (strong recommendation, moderate-quality evidence). Dr Waleed Kh. Mahrous http://www.gastro.org/journals-publications/news/AGA-Introduces-New-Guideline-for-Crohn-s-Disease
  4. 4. Recommendations for the induction of remission  We recommend using anti-TNF-α drugs in combination with thiopurines over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn’s disease (strong recommendation, high-quality evidence).  We suggest using anti-TNF-α drugs in combination with thiopurines over anti-TNF-α drug monotherapy to induce remission in patients who have moderately severe Crohn’s disease (weak recommendation, moderatequality evidence). Dr Waleed Kh. Mahrous http://www.gastro.org/journals-publications/news/AGA-Introduces-New-Guideline-for-Crohn-s-Disease
  5. 5. Recommendations for maintenance of remission  We recommend using thiopurines over no immunomodulator therapy to maintain a steroid-induced remission in patients with Crohn’s disease (strong recommendation, moderatequality evidence).  We suggest using methotrexate over no immunomodulator therapy to maintain a steroid-induced remission in patients with Crohn’s disease (weak recommendation, low-quality evidence). Dr Waleed Kh. Mahrous http://www.gastro.org/journals-publications/news/AGA-Introduces-New-Guideline-for-Crohn-s-Disease
  6. 6. Recommendations for maintenance of remission  We recommend using anti-TNF-α drugs over no anti-TNF-α drugs to maintain a steroid or antiTNF-α drug-induced remission in patients with Crohn’s disease (strong recommendation, high-quality evidence).  We make no recommendation for or against the combination of an anti-TNF-α drug and a thiopurine versus an anti-TNF-α drug alone to maintain remission induced by a combination of these drugs in patients with Crohn’s disease (no recommendation, low-quality evidence). Dr Waleed Kh. Mahrous http://www.gastro.org/journals-publications/news/AGA-Introduces-New-Guideline-for-Crohn-s-Disease

×